drugset / Trial / NCT02844764

Safety & Effectiveness of Autologous Regenerative Cell Therapy on Pain & Inflammation of Osteoarthritis of the Hip

NCT02844764

Phase 2 Recruiting 4000 enrolled VivaTech International, Inc.
NaSingle-groupOpen-labelTreatment

Summary

This is a prospective open-label clinical study of 50 patients to determine safety and treatment potential of autologous cell therapy for pain and inflammation associated with Osteoarthritis of the hip. Follow-up will consist of a larger sample including 4,000 patients.

Timeline

Start
2015-07
Primary completion
2026-08
Completion
2026-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Platelet Rich Plasma Other / unclassified Other
Subject StroMed Cell therapy Other

Indications